Pharmaceutical giant Merck has chosen central London as the site of its new headquarters.
The company’s hub will be home to 150 new researchers, and 800 additional staff. Merck’s other European clinical operations will also move to the site from the company’s current headquarters in Hoddesdon, Hertfordshire.
The American pharmaceutical business has started to look at possible locations for the centre, which is set to open in 2020. Merck said it chose London because the city will facilitate its work with researchers both in the UK and in Europe.
“We believe London to be a unique bioscience centre of excellence and a key component of the established golden triangle for academic science of London-Oxford-Cambridge,” said Louise Houson, managing director, Merck in the UK and Ireland.
Merck chose London as part of a life sciences sector deal with the government.
The government will announce four such sector deals today along with its Industrial Strategy White Paper. Other deals have been struck with the construction, artificial intelligence and automotive industries.
The new partnerships with the government are backed by co-investment from the private sector.
Business Secretary Greg Clark said: “We are an open, flexible economy, built on trade and engagement with the world. We have a competitive business environment with a deserved reputation for being a dependable and confident place to do business, thanks to our high standards, respected institutions and a reliable rule of law.”
The Industrial Strategy will also seek to fix the UK’s productivity problems, Clark said.
By Helen Cahill
Source: City AM
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.